REGULAR SUBMISSION

REGULAR SUBMISSION

EULAR 2025 | REGULAR SUBMISSIONTRACKS AND TOPICSKEYWORDSFORMAT AND LENGTHGENERAL INFORMATION

EULAR 2025 | REGULAR SUBMISSION

Regular Abstract submission is open from 1 October 2024 until 15 January 2025, 23:59 CET. Online publication of accepted abstracts will be approximately two weeks prior to the congress.

Please read all the instructions carefully before preparing and submitting your abstract.

Each abstract must be assigned one of the following tracks, one of the following topics and between two and five of the abstract keywords.

Submit your abstract

TRACKS AND TOPICS

‘Basic’ research is the hypothesis-driven and systematic study of a disease or topic in order to broaden the knowledge base and our understanding of that topic. Basic research typically provides the basis evidence in the form of observations and facts, but do not have specific processes or products in mind.

 ‘Translational’ research refers to several stages which aims to progress the findings of basic research. The first stage bridges the gap between Basic Science and Clinical Research. This stage of translational research advances the findings of basic science by designing and implementing studies to examine previously findings in models without direct implementation in humans; this could be cell cultures or animal models, or even computer simulations. Further stages of Translational research aim to implement these initial ‘pre-clinical’ findings into controlled studies investigating patient populations, and beyond that, into widespread clinical trials and care, and, ultimately, into population-level research.

TOPICS

  1. Antiphospholipid syndrome
  2. Autoinflammatory disease, VEXAS and other monogenic diseases
  3. Behcet's disease
  4. Crystal related disorders
  5. Immunodeficiency
  6. Infection
  7. Infection-related rheumatic diseases
  8. Inflammatory arthritis
  9. Inflammatory myopathies
  10. Juvenile idiopathic arthritis
  11. Metabolic bone diseases and osteoporosis
  12. Mixed connective tissue disease
  13. Osteoarthritis and other mechanical musculoskeletal problems
  14. Other connective tissue diseases
  15. Pain in rheumatic diseases, including fibromyalgia
  16. Psoriatic arthritis
  17. Public and global health
  18. Rheumatoid arthritis
  19. Sarcoidosis
  20. Sjögren's syndrome
  21. Spondyloarthritis
  22. Systemic lupus erythematosus
  23. Systemic sclerosis
  24. Vasculitis, small and medium size vessels
  25. Vasculitis, large vessels including polymyalgia rheumatica
  26. Across diseases
  27. Other diseases
  28. Other topics

‘Clinical’ research explores whether new treatments, medications, devices, and diagnostic techniques and tool are safe, efficacious, and/or cost-effective. Clinical research may take the form of intervention studies (clinical trials) or observational studies, such as case-control, cross-sectional, or longitudinal studies. Where Basic and Translational research is commonly lab-based, clinical research is done in living human volunteers, either healthy or with a specific condition or disease.

TOPICS

  1. Antiphospholipid syndrome
  2. Autoinflammatory disease, VEXAS and other monogenic diseases
  3. Behcet's disease
  4. Crystal related disorders
  5. Immunodeficiency
  6. Infection
  7. Infection-related rheumatic diseases
  8. Inflammatory arthritis
  9. Inflammatory myopathies
  10. Juvenile idiopathic arthritis
  11. Metabolic bone diseases and osteoporosis
  12. Mixed connective tissue disease
  13. Osteoarthritis and other mechanical musculoskeletal problems
  14. Other connective tissue diseases
  15. Pain in rheumatic diseases, including fibromyalgia
  16. Psoriatic arthritis
  17. Public and global health
  18. Rheumatoid arthritis
  19. Sarcoidosis
  20. Sjögren's syndrome
  21. Spondyloarthritis
  22. Systemic lupus erythematosus
  23. Systemic sclerosis
  24. Vasculitis, small and medium size vessels
  25. Vasculitis, large vessels including polymyalgia rheumatica
  26. Across diseases
  27. Other diseases
  28. Other topics


The EULAR HPR (Health Professionals in Rheumatology) community is the network of national organisations of HPR across Europe. It serves as platform for clinical, scientific, and educational activities, collaboration and shared information among the different health professionals working within rheumatology. HPR forms one of EULAR’s three pillars and includes a diverse group of people and professions, including therapeutic and diagnostic professions, epidemiologists, and statisticians, and various other professions such as pharmacists and social workers. Medical doctors, and people with RMDs are included in EULAR’s other pillars.  

TOPICS

29.  HPR Measuring health
30.  HPR Epidemiology and public health
31.  HPR Interventions
32.  HPR Patients' perspectives
33.  HPR Implementation and service evaluation
34.  HPR Professional education, training and competencies

The EULAR PARE (People with Arthritis/Rheumatism in Europe) community is the network of national organisations of people living with rheumatic and musculoskeletal diseases (RMDs) and their support networks. The PARE community is united to ensure the voice of people living with RMDs is heard and has influence among decision makers within Europe, creating powerful alliances that will make a difference to their lives.

PARE forms one of EULAR’s three pillars and includes people living with RMDs and their support networks (as indicated below). Medical doctors and health professionals in rheumatology are included in EULAR’s other pillars.

Here are the different individuals associated with the PARE pillar:

  • People living with RMDs
  • Carers (including friends and family members) of people living with RMDs
  • Patient organisations (at every level, from support groups to medical charities)

TOPICS

35.   PARE Patient information and education
36.   PARE Patient involvement in research
37.   PARE RMD research
38.   PARE Innovations in RMD health care and support
39.   PARE Psychosocial support
40.   PARE Work and rehabilitation
41.   PARE Best practices

Start with the customer – find out what they want and give it to them.

KEYWORDS

Adaptive immunity; Animal Models; Anti-Inflammatory Agents, Non-Steroidal; Artificial Intelligence; Atherosclerosis; Autoantibodies; biological DMARD; Biomarkers; Biosimilar Pharmaceuticals; Bone; Cardiovascular system; Cartilage; Clinical Trial; Cognitive Function and Mental Health; Comorbidities; Cytokines and Chemokines; Descriptive Studies; Diagnostic test; Diet and Nutrition; Disease-modifying Drugs (DMARDs); Diversity, Equity, and Inclusion (DEI); Economics; Education; Enteritis; Epidemiology; Epitranscriptomics, epigenetics, and genetics; Fatigue; Fibroblasts; Gastrointestinal tract; Geographical differences; Global Health; Glucocorticoids; Health services research; Imaging; Infection; Innate immunity; Interdisciplinary research; Lifestyles; Lungs; Magnetic Resonance Imaging; Microbiome; Non-pharmacological interventions; Nursing; Observational studies/registry; Occupational therapy; -omics; Oncology; Outcome measures; Pain; Patient organisations; Patient Reported Outcome Measures; Patient-led research; Physical therapy, Physiotherapy, and Physical Activity; Pregnancy and reproduction; Prognostic factors; Public health; Qualitative research; Quality of care; Quality of life; Randomised controlled trial; Rare/orphan diseases; Real-world evidence; Registries; Rehabilitation; Remission; Renal System; Safety; Sarcopenia; Self-management; Skin; Social work; Synovium; Systematic review; Tapering; Targeted synthetic drugs; Telemedicine, digital health, and measuring health; Ultrasound; Uveitis; Vaccination/Immunisation; Validation; Work-related issues

FORMAT AND LENGTH

It is mandatory to use the abstract word template provided by the system. Please read all instructions carefully before preparing your abstract. 

Counting towards the 5000 characters for Regular Submissions:

  • Abstract title (minimum 15, maximum 300 characters)
  • Headings and content of the abstract template, structured into the following sections:
    • a. Background
    • b. Objectives
    • c. Methods
    • d. Results
    • e. Conclusions
    • f. References (optional)

Characters not counted, but part of final abstract:

  • Author first names, middle initials and last names
  • Author affiliations
  • Acknowledgements including working group
  • Working group + "on behalf of" if entered
  • Abstract number
  • DOI (Declaration of conflict of interest)
  • Invisible characters such as spaces

Table and figures:

A total maximum of any two figures, graphs, images or tables is allowed per abstract, e.g. 1 graph and 1 table, or 2 graphs, or 2 images. Multi-panel figures are allowed.

Abstracts with one or more tables should not have more than 12 columns or 20 rows. Tables turned into pictures/images are accepted, they but should have sufficient quality that everything is readable. Data in images cannot be edited after the abstract has been accepted.

Abstracts can be re-edited and modified until the submission deadline. After the submission deadline, NO modification will be accepted by the EULAR team.

GENERAL INFORMATION


​General Information

Back to the top​

 Not yet available.

 Not yet available.